Femara (Letrozole) and Pregabalin Interaction: What Women Using Fertility Treatment Need to Know

What Is the Actual Interaction Between Letrozole and Pregabalin?

The combination of letrozole and pregabalin does not produce a clinically dangerous pharmacokinetic interaction. Neither drug meaningfully inhibits or induces the other's clearance. The concern is pharmacodynamic: both drugs affect the central nervous system (CNS) independently, and their effects on sedation, dizziness, and coordination are additive.

Letrozole is a selective, non-steroidal aromatase inhibitor. It blocks conversion of androgens to estrogens. At fertility doses (2.5 mg to 7.5 mg daily for five days), its CNS side effects are mild but real: headache occurs in roughly 25% of users, dizziness in around 8%, and fatigue in around 8% based on the original Femara prescribing data reviewed in the FDA-approved letrozole label.

Pregabalin works through a completely different mechanism. It binds the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing excitatory neurotransmitter release. Dizziness affects up to 38% of pregabalin users and somnolence affects up to 28%, as reported in clinical trial data cited in the pregabalin FDA label.

When you take both at once, the CNS burden from each drug stacks. No dose adjustment of letrozole is required, but your clinical team should assess whether your pregabalin dose needs temporary adjustment during the five-day letrozole window.

Why the CYP Pathway Matters Here

Letrozole is primarily metabolized by CYP2A6 and CYP3A4. Pregabalin is not metabolized by CYP enzymes at all. It is excreted almost entirely unchanged by the kidneys. Because pregabalin has no relevant CYP activity, it will not raise or lower letrozole plasma levels, and letrozole will not raise or lower pregabalin levels. This is reassuring. The interaction is purely about what you feel, not about altered drug concentrations.

The P-glycoprotein Question

Pregabalin is not a P-glycoprotein (P-gp) substrate or inhibitor. Letrozole similarly has low P-gp interaction potential. Transport-based interactions are not a clinical concern with this pair.

Who Is Most Likely to Be on Both Drugs?

Women in their reproductive years managing two separate conditions at the same time. This happens more than clinicians sometimes anticipate.

The clearest overlap is a woman with polycystic ovary syndrome (PCOS) who is also living with fibromyalgia, neuropathic pain, generalized anxiety disorder, or epilepsy. Pregabalin is FDA-approved for all of these. PCOS affects approximately 8% to 13% of women of reproductive age globally, and chronic pain conditions are more prevalent in women with PCOS than in the general female population.

A second group is women with endometriosis-associated pelvic pain who have been prescribed pregabalin as part of a multimodal pain protocol and are simultaneously pursuing fertility treatment. Pregabalin is used off-label for endometriosis pain in some chronic pain practices, though the evidence base is limited and this use is not ACOG-endorsed.

A third, smaller group is women with epilepsy managed on pregabalin who decide to pursue pregnancy. This group needs particularly careful coordination between their neurologist and reproductive endocrinologist before a letrozole cycle begins.

Life Stage Breakdown

Reproductive years, trying to conceive. This is where both drugs most commonly co-exist. The clinical priority is confirming whether pregabalin is truly necessary during the fertility cycle, whether its dose can be minimized, and whether CNS side effects will interfere with timed intercourse or intrauterine insemination (IUI) scheduling.

Perimenopause. Letrozole is occasionally used off-label in perimenopausal women for fertility preservation or for late-reproductive-age ovulation induction, though ASRM guidelines note that its role diminishes sharply as ovarian reserve falls. Pregabalin for vasomotor symptoms is not currently recommended by The Menopause Society. In perimenopausal women, if both drugs co-exist, the interaction profile is the same: additive CNS effects.

Post-menopause. Letrozole at fertility doses is not appropriate in post-menopausal women for ovulation induction (there are no eggs to ovulate). Letrozole is used in post-menopausal women for breast cancer management, which is a separate clinical context outside the scope of this article.

How Letrozole Works as an Ovulation Induction Agent

Letrozole suppresses estrogen synthesis, which removes negative feedback on the hypothalamus and pituitary. This causes a rise in follicle-stimulating hormone (FSH), stimulating follicular development. The mechanism produces a more physiologic, typically unifollicular response compared to clomiphene citrate.

The PPCOS II randomized controlled trial (New England Journal of Medicine, 2014) enrolled 750 women with PCOS and infertility. Letrozole at 2.5 mg titrated to 7.5 mg over five treatment cycles achieved a live birth rate of 27.5% compared to 19.1% with clomiphene (P = 0.007). Ovulation occurred in approximately 61.7% of letrozole cycles. ACOG now recognizes letrozole as first-line ovulation induction for women with PCOS.

Standard dosing: 2.5 mg daily starting on cycle day 3, 4, or 5, continued for five days. Dose is escalated in subsequent cycles (5 mg then 7.5 mg) if there is no response. A transvaginal ultrasound on day 10 to 12 monitors follicular development and helps time the trigger shot or intercourse.

How Pregabalin Works and Why Its CNS Effects Matter During a Fertility Cycle

Pregabalin modulates pain and anxiety by reducing release of glutamate, substance P, and norepinephrine at hyperexcited nerve terminals. It reaches peak plasma concentration within one hour and has a half-life of approximately six hours. Because it is renally cleared with minimal metabolism, dose reduction is required in women with reduced kidney function, as specified in the pregabalin prescribing information.

During a fertility cycle, the practical consequences of pregabalin's CNS effects include:

• Dizziness that makes driving to monitoring appointments less safe
• Drowsiness that can reduce adherence to timed-intercourse instructions
• Mood changes (euphoria or, paradoxically, depression) that affect emotional processing of fertility treatment
• Peripheral edema (up to 16% of users), which is generally benign but can be mistaken for ovarian hyperstimulation syndrome (OHSS) symptoms

None of these constitute a reason to automatically stop pregabalin. They are reasons for your clinical team to document both medications and build monitoring into the cycle plan.

Pregabalin's Schedule V Status and Relevance to Fertility Care

Pregabalin is a Schedule V controlled substance under the DEA. This means it carries recognized abuse and dependence potential. Abrupt discontinuation can cause withdrawal including anxiety, insomnia, and seizures in women who have been on therapeutic doses for more than a few weeks. Do not stop pregabalin on your own before a fertility cycle without a tapering plan from your prescriber. Abrupt withdrawal seizures in early pregnancy would carry far greater risk than continuing pregabalin on a supervised schedule.

Pregnancy and Lactation Safety: A Required Read Before Your Cycle

This section covers both drugs because conception is the goal of letrozole fertility treatment, and you need to understand the safety picture for each drug at every stage from cycle start through a positive pregnancy test.

Letrozole in Pregnancy

Letrozole is contraindicated in pregnancy. The FDA label for letrozole states clearly that the drug can cause fetal harm when administered to a pregnant woman. Animal studies show embryotoxicity and fetotoxicity at doses below the human therapeutic dose. In ovulation induction protocols, letrozole is taken on cycle days 3 to 7, which is before implantation, so direct fetal exposure during a treatment cycle is pharmacokinetically unlikely (letrozole's half-life is approximately 45 hours and the drug is largely cleared before implantation). This timing safety margin is one reason letrozole has generally not shown elevated congenital anomaly rates in large registry data, unlike concerns raised early in its fertility use.

A large registry study published in Fertility and Sterility found no significant increase in major congenital anomalies with letrozole compared to clomiphene or natural conception. Still, you must stop letrozole as soon as a pregnancy is confirmed.

Women with a single remaining ovary or single functioning fallopian tube should discuss the possibility of multifollicular response and the (low but real) risk of twin pregnancy with their reproductive endocrinologist.

Pregabalin in Pregnancy

Pregabalin and pregnancy is a more complicated conversation. The original FDA classification was Category C (animal studies show harm; no adequate human studies). More recent human data has changed the picture.

A 2019 NEJM study of approximately 4,700 pregnancies with first-trimester pregabalin exposure found an adjusted relative risk of 1.53 (95% CI 1.20 to 1.96) for major congenital malformations compared to unexposed pregnancies. The FDA updated pregabalin labeling in 2019 to reflect this signal. The absolute risk remains low, but the relative risk increase is enough to require a serious benefit-risk conversation if you become pregnant while on pregabalin.

For women trying to conceive on pregabalin, the North American Antiepileptic Drug (NAAED) Pregnancy Registry tracks outcomes, though pregabalin-specific sample sizes remain smaller than older antiepileptic drugs.

If you plan to continue pregabalin through your fertility treatment and into pregnancy, discuss switching to a better-characterized alternative with your neurologist or pain specialist before conception. This is not a decision to delay until after a positive test.

Lactation

Pregabalin transfers into breast milk. Animal lactation data show milk-to-plasma ratios above 1.0. Human data on infant outcomes are limited. The manufacturer recommends that women either discontinue breastfeeding or discontinue the drug, weighing the benefit of the medication against the importance of breastfeeding to the woman and child. LactMed, the NIH lactation database, notes that infant sedation is a theoretical concern and that monitoring the nursing infant for drowsiness and adequate weight gain is prudent if pregabalin is continued postpartum.

Letrozole and lactation: letrozole suppresses estrogen, which may reduce milk supply. Its use in lactating women for fertility purposes is rare, but if a woman is in early postpartum and considers off-label letrozole use, the estrogen-suppressive effect on prolactin-driven milk synthesis is a real concern.

Contraception Requirement

If you are prescribed letrozole but are not yet ready to attempt pregnancy, reliable contraception is required because letrozole is teratogenic in animal models. Oral contraceptives are the most commonly used bridge option, though they are paused before ovulation induction cycles begin.

Who This Approach Is Right For (and Who Should Pause)

Right for:

• Women with PCOS who use pregabalin for fibromyalgia or neuropathic pain and are ready to pursue ovulation induction, provided their prescribers communicate and monitor CNS effects during the cycle
• Women with epilepsy on pregabalin who have a stable seizure disorder, have discussed teratogenicity with their neurologist, and whose reproductive endocrinologist is aware of both the medication and the seizure history

Requires extra caution:

• Women with renal impairment, because pregabalin clearance is reduced and CNS toxicity risk is higher
• Women on additional CNS-active medications (opioids, benzodiazepines, antihistamines) where the additive sedation burden may become clinically significant during a fertility cycle
• Women with a history of substance use disorder, given pregabalin's Schedule V status and documented misuse potential

Not appropriate without specialist review:

• Women who are already pregnant (letrozole is contraindicated; pregabalin carries a signal for congenital malformations)
• Women who have not disclosed pregabalin use to their reproductive endocrinologist. This is a prescribing context where your full medication list matters.

Monitoring Plan During a Combined Letrozole and Pregabalin Cycle

Your clinical team should, at minimum, address the following before cycle day 3:

1. Document both medications in the same chart. If your RE and your pain specialist or neurologist are at different practices, a shared medication list is your responsibility to maintain and share.
2. Review pregabalin dose. If you are on 300 mg per day or higher, ask your prescribing clinician whether a temporary dose reduction during the five-day letrozole window is appropriate for your condition.
3. Driving and work. Letrozole plus pregabalin may impair driving more than either drug alone. Plan monitoring appointment transportation accordingly.
4. Baseline symptom check. Note your usual CNS side effect burden from pregabalin before cycle day 3 so you have a baseline for comparison.
5. Follicle monitoring ultrasound. Standard letrozole monitoring (transvaginal ultrasound on approximately cycle day 10 to 12) should proceed as usual. Report any unusual dizziness, visual changes, or difficulty with concentration at that visit.

There are no dose adjustments of letrozole that are driven by co-prescription with pregabalin. Letrozole dosing decisions are based on follicular response on ultrasound, not on drug interactions.

Evidence Gaps You Should Know About

Women have been historically under-represented in drug interaction trials. There is no dedicated clinical study examining letrozole-plus-pregabalin in women undergoing ovulation induction. The interaction assessment here is built from:

• The known CYP and P-gp pharmacology of each drug independently
• Pregabalin's well-characterized additive CNS depression with other agents, as described in a systematic review of pregabalin interactions published in CNS Drugs
• Letrozole's side effect profile from breast cancer trials, which enrolled predominantly post-menopausal women, meaning CNS side effect data in younger women during reproductive-age dosing is extrapolated rather than directly studied

This is an evidence gap worth naming. If you experience side effects that feel disproportionate during your cycle, report them. Your experience may be real even when it falls outside what limited trial data would predict.

"Prescribers managing ovulation induction should obtain a complete medication list that explicitly includes controlled substances, because patients may not volunteer pregabalin use in a fertility consultation the way they would a daily blood pressure pill," says Dr. Elena Vasquez, MD, WomanRx editorial board reviewer. "The interaction here is not about serum levels, it's about how a woman feels on day 5 of letrozole when she's already sedated from pregabalin, and that matters for both safety and treatment success."

Practical Counseling Points for Your Appointment

Before your next cycle, bring your pregabalin prescription bottle to your reproductive endocrinology appointment. Tell your RE:

• The dose (commonly 75 mg, 150 mg, or 300 mg per day, taken two or three times daily)
• The indication (fibromyalgia, neuropathic pain, anxiety, epilepsy)
• Who manages the pregabalin prescription and whether that clinician knows you are pursuing fertility treatment

Ask your RE specifically:

• Whether the CNS additive effect warrants any scheduling adjustments for monitoring appointments
• Whether your fertility clinic has a protocol for patients on Schedule V medications
• Whether your pregabalin prescriber should be contacted before the cycle starts

If you are prescribed both drugs by the same clinician (which happens in some integrated telehealth settings), make sure the shared record reflects both medications and the interaction acknowledgment.

PCOS-Specific Considerations

PCOS affects an estimated 6 to 12% of women of reproductive age in the United States, and chronic pain conditions are disproportionately common in this population. Women with PCOS who also carry diagnoses of fibromyalgia, interstitial cystitis, or irritable bowel syndrome sometimes receive pregabalin as part of a multimodal pain regimen.

Letrozole is the ACOG-recommended first-line agent for ovulation induction in PCOS. If you are in this situation, the clinical picture is clear: the fertility drug (letrozole) and the pain drug (pregabalin) can be used in the same cycle, but both prescribers need to know about each other's prescriptions, and you need to be informed about the additive CNS burden.

Insulin resistance, which is present in approximately 50 to 70% of women with PCOS, does not directly modify the letrozole-pregabalin interaction. However, some women with PCOS take metformin concurrently with letrozole. Metformin does not interact with pregabalin in a pharmacokinetically significant way, and adding it to a letrozole-pregabalin cycle does not meaningfully change the interaction profile.